Loading
A phase 3 trial of Pembrolizumab, Etoposide, Cisplatin, Atezolizumab and Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) is a phase 3 interventional study registered as NCT05224141 by Merck Sharp & Dohme LLC, with 460 participants enrolled, started 2022-03-24 and due to reach its primary completion in 2024-06-04. Interventions recorded: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab and Carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
460 enrolled.
95% CI 9.8 to 12.6; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication · 95% CI 11.6 to 14.8
Source95% CI 4.4 to 5.4; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication · 95% CI 4.4 to 5.3
Source95% CI 65.4 to 77.5; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication · 95% CI 68.7 to 80.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Pembrolizumab/Vibostolimab | 230 | 11.5 months | 1.26 (1 to 1.59) | 0.9762 | link |
| Atezolizumab | 230 | 12.9 months | ||||
| Progression-Free Survival (PFS) | Pembrolizumab/Vibostolimab | 230 | 5.3 months | 1.01 (0.82 to 1.23) | 0.5316 | link |
| Atezolizumab | 230 | 4.5 months | ||||
| Objective Response Rate (ORR) | Pembrolizumab/Vibostolimab | 230 | 71.7% | - | - | link |
| Atezolizumab | 230 | 74.8% |
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Etoposide, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Merck & Co. (MSD), Small-cell lung cancer, Pembrolizumab and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin, Pembrolizumab and the tag pipeline.